The U.S. Food and Drug Administration has expanded the approval of Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older.
Perennial readers of the healthcare industry’s tea leaves, IQVIA — née QuintilesIMS — is once again looking into what the future holds for the healthcare market. The IQVIA Institute for Human Data and Science recently released its report on where the global health market is headed in the next five years.
Automation and Technology
Drug Store News sat down with Stuart Amos to talk about FlavoRx, its start and where the company sees itself in the marketplace today and in the future.